1132641-22-5
Chemical Structure
Rosiglitazone-d3
- CAS No.: 1132641-22-5
- Formula:C18H16D3N3O3S
- Molecular Weight:360.45
IUPAC Name: 5-(4-(2-((methyl-d3)(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
InChIKey: YASAKCUCGLMORW-FIBGUPNXSA-N
SMILES: O=C(N1)C(CC2=CC=C(OCCN(C3=NC=CC=C3)C([2H])([2H])[2H])C=C2)SC1=O
Biological Activity: Rosiglitazone-d3 is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rosiglitazone-d3 | Rosiglitazone-d3 is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rosiglitazone (Standard) | 99.59% | Rosiglitazone (Standard) is the analytical standard of Rosiglitazone. This product is intended for research and analytical applications. Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rosiglitazone-d4 | Rosiglitazone-d4 is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rosiglitazone-d4-1 | Rosiglitazone-d4-1 (BRL 49653-d4-1) is deuterium-labeled Rosiglitazone (HY-17386). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rosiglitazone | 99.94% | Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM), with blood-brain barrier permeability. Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6. [Content Brief]
- [3]. Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8. [Content Brief]
- [4]. Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70. [Content Brief]
